Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Cancer

05-01-2024 | Gastric Cancer | Review

Gastric Cancer Survivorship: Multidisciplinary Management, Best Practices and Opportunities

Authors: Era Cobani, Mohammed Najeeb Al Hallak, Anthony F. Shields, Jordan Maier, Thomas E. Kelly, Niren Naidoo, Miguel Tobon, Steve Kim, Eliza W. Beal

Published in: Journal of Gastrointestinal Cancer

Login to get access

Abstract

Purpose

Gastric cancer is the 5th most common malignancy worldwide. As early detection increases and treatments for gastric cancer improve, the number of gastric cancer survivors grows.

Methods

Here, we review the diagnosis and management of gastric cancer and discuss important considerations for gastric cancer survivorship including cancer surveillance, weight loss, malnutrition, fatigue, specific complications related to surgery and radiation, quality of life in gastric cancer survivorship, health behavior, and models of survivorship.

Results

Multimodality therapy with chemotherapy and surgery can result in chronic toxicities in multiple organ systems. This emphasizes the need for a multidisciplinary survivorship care model including cancer surveillance, management of chronic toxicities, and optimization of modifiable risk factors with long-term involvement of appropriate providers.

Conclusion

Adequately caring for gastric cancer survivors requires a coordinated, multidisciplinary approach.
Literature
1.
Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: a population-based modelling study. EClinicalMedicine. 2022;47: 101404.PubMedPubMedCentralCrossRef
2.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef
3.
4.
Zhao J-K, Wu M, Kim CH, et al. Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province. China Eur J Cancer Prev. 2017;26:357–64.PubMedCrossRef
5.
6.
7.
Zhu H, Yang X, Zhang C, et al. Red and processed meat intake is associated with higher gastric cancer risk: a meta-analysis of epidemiological observational studies. PLoS ONE. 2013;8: e70955.PubMedPubMedCentralCrossRef
8.
D’Elia L, Galletti F, Strazzullo P. Dietary salt intake and risk of gastric cancer. 2014, pp. 83–95.
9.
Bouvard V, Loomis D, Guyton KZ, et al. Carcinogenicity of consumption of red and processed meat. Lancet Oncol. 2015;16:1599–600.PubMedCrossRef
10.
Lee T-Y, Chiang E-P, Shih Y-T, et al. Lower serum folate is associated with development and invasiveness of gastric cancer. World J Gastroenterol. 2014;20:11313–20.PubMedPubMedCentralCrossRef
11.
12.
Wang P-L, Xiao F-T, Gong B-C, et al. Alcohol drinking and gastric cancer risk: a meta-analysis of observational studies. Oncotarget. 2017;8:99013–23.PubMedPubMedCentralCrossRef
13.
Gupta S, Tao L, Murphy JD, et al. Race/ethnicity-, socioeconomic status-, and anatomic subsite-specific risks for gastric cancer. Gastroenterology. 2019;156:59-62.e4.PubMedCrossRef
14.
Tavakoli A, Monavari SH, Solaymani Mohammadi F, et al. Association between Epstein-Barr virus infection and gastric cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20:493.PubMedPubMedCentralCrossRef
15.
16.
Takeno S, Hashimoto T, Maki K, et al. Gastric cancer arising from the remnant stomach after distal gastrectomy: a review. World J Gastroenterol. 2014;20:13734–40.PubMedPubMedCentralCrossRef
17.
Edgren G, Hjalgrim H, Rostgaard K, et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol. 2010;172:1280–5.PubMedCrossRef
18.
19.
Kim TH, Kim IH, Kang SJ, et al. Korean Practice Guidelines for Gastric Cancer 2022: an evidence-based, multidisciplinary approach. J Gastric Cancer. 2023;23:3.PubMedPubMedCentralCrossRef
20.
Ahmad SA, Xia BT, Bailey CE, et al. An update on gastric cancer. Curr Probl Surg. 2016;53:449–90.PubMedCrossRef
21.
Mukkamalla SKR, Recio-Boiles A, Babiker HM. Gastric Cancer. 2023.
22.
Hejna M, Wöll E, Tschandl P, et al. Cutaneous paraneoplastic disorders in stomach cancer: collaboration between oncologically active dermatologists and clinical oncologists. Crit Rev Oncol Hematol. 2016;103:78–85.PubMedCrossRef
23.
24.
25.
Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23:2656–62.PubMedCrossRef
26.
Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. 2023;401:1655–68.
27.
Shitara K, Xu R-H, Moran DM, et al. Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW). 2023;41:4035–35. https://​doi.​org/​10.​1200/​JCO20234116_​suppl4035.
28.
Xiang Y-Y, Deng C-C, Liu H-Y, et al. The prognostic effect of multidisciplinary team intervention in patients with advanced gastric cancer. Curr Oncol. 2022;29:1201–12.PubMedPubMedCentralCrossRef
29.
Ju M, Wang SC, Syed S, et al. Multidisciplinary teams improve gastric cancer treatment efficiency at a large safety net hospital. Ann Surg Oncol. 2020;27:645–50.PubMedCrossRef
30.
31.
Cardoso R, Coburn NG, Seevaratnam R, et al. A systematic review of patient surveillance after curative gastrectomy for gastric cancer: a brief review. Gastric Cancer. 2012;15:164–7.CrossRef
32.
Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2016;27:v38–49.PubMedCrossRef
33.
Forbes N, Elhanafi SE, Al-Haddad MA, et al. American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: summary and recommendations. Gastrointest Endosc. 2023;98:271–84.PubMedCrossRef
34.
Group DGCS, Sasako M. Risk factors for surgical treatment in the Dutch gastric cancer trial. Br J Surg. 2005;84:1567–71.
35.
Park SH, Lim DH, Sohn TS, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆ Epub ahead of print 2021. https://​doi.​org/​10.​1016/​j.​annonc.​2020.​11.​017.
36.
Cats A, Jansen EPM, van Grieken NCT, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:616–28.PubMedCrossRef
37.
Degiuli M, Reddavid R, Tomatis M, et al. D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial. Eur J Cancer. 2021;150:10–22.PubMedCrossRef
38.
Nunobe S, Ida S. Current status of proximal gastrectomy for gastric and esophagogastric junctional cancer: a review. Ann Gastroenterol Surg. 2020;4:498–504.PubMedPubMedCentralCrossRef
39.
Elimova E, Janjigian YY, Mulcahy M, et al. It is time to stop using epirubicin to treat any patient with gastroesophageal adenocarcinoma. J Clin Oncol. 2017;35:475–7.PubMedCrossRef
40.
Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. The Lancet. 2019;393:1948–57.CrossRef
41.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010;376:687–97.CrossRef
42.
Shitara K, Bang Y-J, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419–30.PubMedCrossRef
43.
Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600:727–30.PubMedPubMedCentralCrossRef
44.
Shin C-H, Lee W-Y, Hong S-W, et al. Characteristics of gastric cancer recurrence five or more years after curative gastrectomy. Chin J Cancer Res. 2016;28:503–10.PubMedPubMedCentralCrossRef
45.
Jin LX, Moses LE, Squires MH, et al. Factors associated with recurrence and survival in lymph node–negative gastric adenocarcinoma. Ann Surg. 2015;262:999–1005.PubMedCrossRef
46.
Wang HM, Huang CM, Zheng CH, et al. Tumor size as a prognostic factor in patients with advanced gastric cancer in the lower third of the stomach. World J Gastroenterol. 2012;18:5470–5.PubMedPubMedCentralCrossRef
47.
Deng J, Zhang R, Pan Y, et al. Tumor size as a recommendable variable for accuracy of the prognostic prediction of gastric cancer: a retrospective analysis of 1,521 patients. Ann Surg Oncol. 2015;22:565–72.PubMedCrossRef
48.
49.
50.
51.
52.
Tanabe K, Takahashi M, Urushihara T, et al. Predictive factors for body weight loss and its impact on quality of life following gastrectomy. World J Gastroenterol. 2017;23:4823–30.PubMedPubMedCentralCrossRef
53.
Davis JL, Selby LV, Chou JF, et al. Patterns and predictors of weight loss after gastrectomy for cancer. Oncol. 2016;23:1639–45.
54.
Pachman DR, Barton DL, Swetz KM, et al. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 2012;30:3687–96.PubMedCrossRef
55.
Hwang IC, Yun YH, Kim YW, et al. Factors related to clinically relevant fatigue in disease-free stomach cancer survivors and expectation-outcome consistency. Support Care Cancer. 2014;22:1453–60.PubMedCrossRef
56.
Kobayashi D, Kodera Y, Fujiwara M, et al. Assessment of quality of life after gastrectomy using EORTC QLQ-C30 and STO22. World J Surg. 2011;35:357–64.PubMedCrossRef
57.
Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer. 1996;4:82–96.PubMedCrossRef
58.
Finsterer J, Mahjoub SZ. Fatigue in healthy and diseased individuals. Am J Hosp Palliat Med. 2014;31:562–75.CrossRef
59.
Al Maqbali M, Al Sinani M, Al Naamani Z, et al. Prevalence of fatigue in patients with cancer: a systematic review and meta-analysis. J Pain Symptom Manage. 2021;61:167-189.e14.PubMedCrossRef
60.
61.
Abdel-Razeq H, Hashem H. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Crit Rev Oncol Hematol. 2020;145: 102837.PubMedCrossRef
62.
63.
Pachman DR, Price KA, Carey EC. Nonpharmacologic approach to fatigue in patients with cancer. Cancer Journal (United States). 2014;20:313–8.
64.
65.
Singh B, Spence RR, Steele ML, et al. A systematic review and meta-analysis of the safety, feasibility, and effect of exercise in women with stage II+ breast cancer. Arch Phys Med Rehabil. 2018;99:2621–36.PubMedCrossRef
66.
67.
Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol. 2014;32:335–46.PubMedCrossRef
68.
Baguley B, Bolam K, Wright O, et al. The effect of nutrition therapy and exercise on cancer-related fatigue and quality of life in men with prostate cancer: a systematic review. Nutrients. 2017;9:1003.PubMedPubMedCentralCrossRef
69.
Singh B, Hayes SC, Spence RR, et al. Exercise and colorectal cancer: a systematic review and meta-analysis of exercise safety, feasibility and effectiveness. Int J Behav Nutr Phys Act. 2020;17:122.PubMedPubMedCentralCrossRef
70.
Vermaete N, Wolter P, Verhoef G, et al. Physical activity, physical fitness and the effect of exercise training interventions in lymphoma patients: a systematic review. Ann Hematol. 2013;92:1007–21.PubMedCrossRef
71.
72.
73.
Brown JC, Huedo-Medina TB, Pescatello LS, et al. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiol Biomark Prev. 2011;20:123–33.CrossRef
74.
75.
Paulsen Ø, Klepstad P, Rosland JH, et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol. 2014;32:3221–8.PubMedCrossRef
76.
Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31:3076–82.PubMedCrossRef
77.
Oh HJ, Yoon BH, Ha YC, et al. The change of bone mineral density and bone metabolism after gastrectomy for gastric cancer: a meta-analysis. Osteoporos Int. 2020;31:267–75.PubMedCrossRef
78.
Shahraki MS, Mahmoudieh M, Kalidari B, et al. Bone health after bariatric surgery: consequences, prevention, and treatment. Adv Biomed Res. 2022;11:92.CrossRef
79.
Shin DW, Suh B, Suh B, et al. Increased risk of osteoporotic fracture in postgastrectomy gastric cancer survivors compared with matched controls: a nationwide cohort study in Korea. Am J Gastroenterol. 2019;114:1735–43.PubMedCrossRef
80.
81.
Climent M, Pera M, Aymar I, et al. Bone health in long-term gastric cancer survivors: a prospective study of high-dose vitamin D supplementation using an easy administration scheme. J Bone Miner Metab. 2018;36:462–9.PubMedCrossRef
82.
Mott A, Bradley T, Wright K, et al. Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials. Osteoporos Int. 2019;30:1543–59.PubMedCrossRef
83.
Farsinejad-Marj M, Saneei P, Esmaillzadeh A. Dietary magnesium intake, bone mineral density and risk of fracture: a systematic review and meta-analysis. Osteoporos Int. 2016;27:1389–99.PubMedCrossRef
84.
Davis JL, Ripley RT. Postgastrectomy syndromes and nutritional considerations following gastric surgery. Surg Clin North Am. 2017;97:277–93.PubMedCrossRef
85.
86.
Enani G, Bilgic E, Lebedeva E, et al. The incidence of iron deficiency anemia post-Roux-en-Y gastric bypass and sleeve gastrectomy: a systematic review. Surg Endosc. 2020;34:3002–10.PubMedCrossRef
87.
Lim C-H, Kim SW, Kim WC, et al. Anemia after gastrectomy for early gastric cancer: long-term follow-up observational study. World J Gastroenterol. 2012;18:6114–9.PubMedPubMedCentralCrossRef
88.
Mukoyama T, Kanaji S, Sawada R, et al. Assessment of risk factors for delayed gastric emptying after distal gastrectomy for gastric cancer. Sci Rep. 2022;12:15903.PubMedPubMedCentralCrossRef
89.
Yang J-Y, Lee H-J, Alzahrani F, et al. Postprandial changes in gastrointestinal hormones and hemodynamics after gastrectomy in terms of early dumping syndrome. J Gastric Cancer. 2020;20:256–66.PubMedPubMedCentralCrossRef
90.
Blouhos K, Boulas KA, Tsalis K, et al. Management of afferent loop obstruction: reoperation or endoscopic and percutaneous interventions? World J Gastrointest Surg. 2015;7:190–5.PubMedPubMedCentralCrossRef
91.
Termsinsuk P, Chantarojanasiri T, Pausawasdi N. Diagnosis and treatment of the afferent loop syndrome. Clin J Gastroenterol. 2020;13:660–8.PubMedCrossRef
92.
Chen G, Yu Z, Zhang Y, et al. Radiation-induced gastric injury during radiotherapy: molecular mechanisms and clinical treatment. J Radiat Res. 2023;1–10.
93.
Shadad AK, Sullivan FJ, Martin JD, et al. Gastrointestinal radiation injury: symptoms, risk factors and mechanisms. World J Gastroenterol: WJG. 2013;19:185–98.PubMedPubMedCentralCrossRef
94.
Hu Y, Vos EL, Baser RE, et al. longitudinal analysis of quality-of-life recovery after gastrectomy for cancer. Ann Surg Oncol. 2021;28:48–56.PubMedCrossRef
95.
Karanicolas PJ, Graham D, Gönen M, et al. Quality of life after gastrectomy for adenocarcinoma: a prospective cohort study. Ann Surg. 2013;257:1039–46.PubMedCrossRef
96.
Brenkman HJF, Tegels JJW, Ruurda JP, et al. Factors influencing health-related quality of life after gastrectomy for cancer. Gastric Cancer. 2018;21:524–32.PubMedCrossRef
97.
Akkerman RDL, Haverkamp L, van Rossum PSN, et al. Long-term quality of life after oesophagectomy with gastric conduit interposition for cancer. Eur J Cancer. 2015;51:1538–45.PubMedCrossRef
98.
Arndt V, Merx H, Stürmer T, et al. Age-specific detriments to quality of life among breast cancer patients one year after diagnosis. Eur J Cancer. 2004;40:673–80.PubMedCrossRef
99.
100.
101.
102.
Han KH, Hwang IC, Kim S, et al. Factors associated with depression in disease-free stomach cancer survivors. J Pain Symptom Manage. 2013;46:511–22.PubMedCrossRef
103.
Zhang J kui, Fang L li, Zhang D wei, et al. Type D personality in gastric cancer survivors: association with poor quality of life, overall survival, and mental health. J Pain Symptom Manage. 2016;52:81–91.
104.
Kim M, Choi KS, Suh M, et al. Risky lifestyle behaviors among gastric cancer survivors compared with matched non-cancer controls: results from baseline result of community based cohort study. Cancer Res Treat. 2018;50:738–47.PubMedCrossRef
105.
Han CJ, Tounkara F, Kalady M, et al. Risk factors of health-related quality of life among gastrointestinal cancer survivors in the U.S.: with a focus on social and behavioral determinants of health (SBDH). Int J Environ Res Public Health. 2023;20:6676.
106.
107.
Pinheiro LC, Wheeler SB, Chen RC, et al. The effects of cancer and racial disparities in health-related quality of life among older Americans: a case-control, population-based study. Cancer. 2015;121:1312–20.PubMedCrossRef
108.
Hamakawa T, Kurokawa Y, Mikami J, et al. Risk factors for postoperative complications after gastrectomy in gastric cancer patients with comorbidities. Surg Today. 2016;46:224–8.PubMedCrossRef
109.
110.
111.
112.
Partridge EE, Campos SM, Farmer M, et al. NCCN Guidelines index cervical cancer screening toc discussion continue * nccn guidelines panel disclosures nccn guidelines version 2.2012 Panel Members Cervical Cancer Screening. 2012.
113.
114.
115.
Ward EM, Flowers CR, Gansler T, et al. The importance of immunization in cancer prevention, treatment, and survivorship. CA Cancer J Clin. 2017;67:398–410.PubMedCrossRef
116.
Lee JE, Shin DW, Lee H, et al. One-year experience managing a cancer survivorship clinic using a shared-care model for gastric cancer survivors in Korea. J Korean Med Sci. 2016;31:859.PubMedPubMedCentralCrossRef
117.
Sitte J, Frentiu E, Baumann C, et al. Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: a prospective cohort study of methods for improving coverage. Aliment Pharmacol Ther. 2019;49:84–90.PubMedCrossRef
118.
Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–99.
119.
Metadata
Title
Gastric Cancer Survivorship: Multidisciplinary Management, Best Practices and Opportunities
Authors
Era Cobani
Mohammed Najeeb Al Hallak
Anthony F. Shields
Jordan Maier
Thomas E. Kelly
Niren Naidoo
Miguel Tobon
Steve Kim
Eliza W. Beal
Publication date
05-01-2024
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-023-01001-7
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits